Empe Diagnostics Private Limited - Due diligence report

A 360° intelligence report on Empe Diagnostics: trust score, financial health, credit view, compliance, directors, growth and distress signa…

2019-10-30 Hyderabad, Telangana Active Unlisted
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Empe Diagnostics — 360° Intelligence Report

Generated from MCA filings & public records
84/100
Trust Score
Low Risk

Empe Diagnostics is assessed as Low Risk with a Trust Score of 84/100. Empe Diagnostics is an active private limited indian non-government company incorporated in 2019, operating in the Healthcare sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 27 Oct 2026 from the latest processed filings. Empe Diagnostics Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 80/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
Jan Buch Andersen 01234567 Director 01/04/2018 6 yrs Approved
Chandran Dev 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Empe Diagnostics Ab
Subsidiaries
-
Group entities
-
Capital events
7 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Empe Diagnostics Ab Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 6 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
MSME payment delays disclosed - latest outstanding 4.98 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Aug 2024
Director ceased
PAVANKUMAR ASALAPURAM RAMACHANDRAN
19 Aug 2024
Director appointed
Jan Buch Andersen (Director)
Director appointed
Chandran Dev (Director)
21 Mar 2023
Director ceased
SHARDA BALAJI
30 Sep 2022
Director ceased
RAGHAVENDRA GOUD VAGGU
20 Jan 2022
Director ceased
SANJEEV KUMAR GUPTA
10 Dec 2021
Securities allotted
406057 Equity Shares - 1.22 cr raised
20 Sep 2021
Securities allotted
285542 Equity Shares - 85.66 Lakh raised
19 Apr 2021
Securities allotted
250368 Equity Shares - 75.11 Lakh raised
01 Mar 2021
Securities allotted
291574 Equity Shares - 87.47 Lakh raised
10 Dec 2020
Securities allotted
425757 Equity Shares - 1.28 cr raised
05 Nov 2020
Securities allotted
283343 Equity Shares - 85.00 Lakh raised
26 Jun 2020
Securities allotted
66647 Equity Shares - 19.99 Lakh raised
10

Key Observations

Auto-generated from the data above
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Associated Formulations Private Limited U74999DL2018PTC329571 Rohini, Delhi, India
Tymk Health & Wellness Private Limited U15100GJ2014PTC080500 Savli, Gujarat, India
Kusum Industries Private Limited U24100RJ2014PTC044804 Jaipur, Rajasthan, India
Baxom Healthcare Private Limited U24233GJ2007PTC051134 Rajkot, Gujarat, India
Infinion Biopharma Limited U51909GJ2018PLC100571 Ahmedabad, Gujarat, India
Ronak Life Care Private Limited U24232GJ2007PTC051370 Ahmedabad, Gujarat, India
Devi Chemscience Private Limited U24232PN2012PTC145215 Pune, Maharashtra, India
Malabar Oxygen Company Private Limited U24111GA1984PTC000566 Margao, Goa, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Empe Diagnostics before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Empe Diagnostics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Empe Diagnostics - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Empe Diagnostics pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Empe Diagnostics - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Empe Diagnostics an active company?

Empe Diagnostics has MCA status “Active” with a compliance score of 80/100 (Low Risk).

Is Empe Diagnostics financially healthy?

Empe Diagnostics has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Empe Diagnostics?

Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Empe Diagnostics?

The ultimate holding entity is Empe Diagnostics Ab. 2 active director(s) are on record.

Does Empe Diagnostics have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Empe Diagnostics up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 80/100 (Low Risk).

Is it risky to lend to Empe Diagnostics?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.